Bristol Myers anticipates recovery in sales of hospital-administered drugs, raises annual profit forecast

The U.S. drugmaker expects the ruling and other settlements with generic drugmakers to protect the drug, which accounted for over 21% of its second-quarter sales, at least through 2026.

In the second quarter, drugs such as cancer immunotherapy Opdivo were hurt by fewer visits to the doctor as well as demand from new patients.

Opdivo sales fell 9% to $1.65 billion, roughly in line with analysts' estimates, but the company said it expected the drug to return to growth in 2021.

The company said it was expecting demand from new patients as well as for its products administered by doctors to recover in the third quarter and stabilize in the fourth quarter.

"Overall, this was a solid quarter for Bristol, given the circumstances," said Edward Jones analyst Ashtyn Evans.

Sales of Eliquis, which has been used to treat some COVID-19 patients, rose 6% to $2.16 billion.

Bristol raised the lower end of its full-year adjusted profit range by 10 cents and the top end by 5 cents to $6.10 to $6.25 per share.

Bristol's total revenue rose 61.5% to $10.13 billion, above an estimate of $9.97 billion, according to IBES data from Refinitiv, mainly due to its $74 billion buyout of Celgene.